Strengths

QNRX’s current ratio of 1.76 and quick ratio of 1.76 indicate near-term liquidity coverage, but this is modest versus better-capitalized peers in development-stage biotech.

Net debt to EBITDA of 0.20 suggests limited leverage pressure, yet the metric is less meaningful for peers with negative or volatile EBITDA.

The reported cash conversion cycle is deeply negative, implying favorable working-capital timing, although this can be distorted by small-base or nonrecurring balance-sheet effects.

Return on invested capital of -3.59% shows capital is not yet generating peer-level returns, limiting any structural strength from operating efficiency.

Weaknesses

Return on invested capital of -3.59% signals persistent value destruction, leaving QNRX structurally weaker than profitable peers that compound capital internally.

The absence of reported operating and gross margins suggests limited current earnings quality, which compares unfavorably with peers that already demonstrate scalable margin profiles.

Liquidity is only adequate rather than robust, because current and quick ratios near 1.76 provide less cushion than stronger peers with larger cash buffers.

A near-zero debt-to-equity ratio does not offset weak profitability, since peers with stronger balance sheets still pair leverage discipline with positive operating returns.

Opportunities

If QNRX converts its liquidity position into sustained clinical or commercial execution, it could narrow the gap with peers that currently monetize capital more effectively.

The low leverage profile leaves room for financing flexibility relative to more indebted peers, which can support development spending without immediate balance-sheet strain.

A deeply negative cash conversion cycle could improve working-capital efficiency further if operational scaling reduces cash tied up in the business.

Because revenue, EPS, and FCF growth data are unavailable, any future inflection in these metrics could materially re-rate QNRX versus slower-growing peers.

Threats

Negative ROIC increases the risk that additional capital raises dilute shareholders faster than peers that already fund growth from internally generated returns.

If operating margins remain unreported or negative, QNRX may lag peers in demonstrating a durable path to profitability and commercial scale.

Development-stage biotech peers with stronger liquidity and validated revenue trajectories can outcompete QNRX for investor capital and strategic attention.

Limited disclosed segment concentration data makes it harder to evidence diversification, leaving QNRX more exposed than peers with broader revenue bases.

Overall Score

QNRX’s structural positioning versus peers is weak because liquidity is only adequate while capital efficiency remains negative, and no durable operating advantage is evident.